Metin Çelik, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Metin Çelik, PhD


Metin Çelik, PhD
President, Pharmaceutical
Technologies
International (PTI)

Metin Çelik is the founder and president of Pharmaceutical Technologies International, Inc., and is also a pharmaceutical processing research professor in the Department of Industrial Engineering at Rutgers University. Prior to that, he was a faculty member at Rutgers’ College of Pharmacy. Çelik received his BSc (Hons.) degree in pharmacy from Hacettepe University-Turkey and was awarded a PhD degree in Pharmaceutical Technology from Leicester Polytechnic-UK. Çelik worked at Sandoz-Switzerland and Sandoz-Turkey before he joined Smith Kline & French Laboratories to establish the first state-of-the-art compaction simulator system in the western hemisphere. He developed the second unit at Rutgers as the first such a unit in academia in the US and established an internationally recognized research center.

Çelik has organized more than 40 national and international symposia and short courses, published more than 30 research articles and book chapters, and made more than 150 presentations at industry and academic meetings. Çelik acted a consultant to FDA and roughly 45 pharmaceutical, nutraceutical, excipient, equipment companies, and law firms worldwide. He currently serves as a member of the editorial board or a reviewer for a numerous pharmaceutical journals. He is the past chair of the American Association of Pharmaceutical Scientists (AAPS) Process Development Focus Group and the founder and the past chair of the AAPS Excipients Focus Group.

Çelik's recent areas of interests include: process analytical technology; development of pharmaceutical expert systems, excipient databases, and management tools in the area of drug delivery technologies; use of compaction simulators in the preformulation and formulation of solid dosage forms; theory and practice of pharmaceutical compaction; excipient functionality testing; and pharmaceutical processing (including milling, mixing, granulation, tableting, and coating).

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here